

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Markku Antilla	Examiner: Shirley V. Gembeh
Appln. No.: 10/777,211	Art Unit: 1614
Filed: February 13, 2004	Confirmation No.: 2487
For: METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE	
Attorney Docket No: 13601-072	

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

In accordance with the duty of disclosure under 37 CFR §1.56 and §§1.97-1.98, and more particularly in accordance with 37 CFR §1.97(c), Applicant hereby cites the following reference(s):

OTHER ART – NON PATENT LITERATURE DOCUMENTS
L.E. Holodov, V.P. Yacovelev, "Clinical Pharmacokinetic", M., Medicine, 1985, Page 87. Translated summary included.

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 CFR §1.98(a)(2). Pursuant to the undersigned attorney's obligation and duties under 37 CFR §§ 1.56 and 1.98(a)(3) and (c), either English language abstracts, partial translations, or full translations are included for patent documents which are not in English for the express purpose of providing a concise explanation of the references to the Patent and Trademark Office with the opportunity to evaluate the same. Applicant respectfully requests the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 CFR §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 CFR §1.56(a).

Applicant has calculated a processing fee in the amount of \$180.00 to be due under 37 CFR §1.17(p) in connection with the filing of this Information Disclosure Statement. Applicant has enclosed a check covering this fee, or authorized charging the fee to a deposit account or credit card, as indicated in the Transmittal accompanying this Information Disclosure Statement.

Respectfully submitted,

September 10, 2009

Date

/William R. Boudreaux/

William R. Boudreaux
(Reg. No. 35,796)